chlorambucil has been researched along with vidarabine in 144 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 25 (17.36) | 18.2507 |
| 2000's | 73 (50.69) | 29.6817 |
| 2010's | 41 (28.47) | 24.3611 |
| 2020's | 5 (3.47) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Phyliky, RL; Tefferi, A | 1 |
| Bladé, J; Cervantes, F; Marín, P; Montserrat, E; Rozman, C; Rozman, M | 1 |
| Ashique, A; Begleiter, A; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L | 1 |
| Bourquard, P; Emberger, JM; Exbrayat, C; Fégueux, N; Lavabre-Bertrand, C; Lavabre-Bertrand, T; Navarro, M; Poncelet, P; Rousset, T; Taïb, J | 1 |
| Bosanquet, AG; Catovsky, D; Crotty, GM; McCann, SR; Mills, MJ | 1 |
| Brugiatelli, M; Callea, I; Callea, V; Iacopino, P; Messina, G; Morabito, F; Nobile, F; Rodinò, A | 1 |
| del Giglio, A; Keating, M; O'Brien, S | 1 |
| Canellakis, ZN; Costin, D; Degar, B; Drygas, JC; Mani, M; Morse, L; Newcomb, EW; Potmesil, M; Rosenberg, CR; Silber, R | 1 |
| Juliusson, G; Liliemark, J | 1 |
| Berman, E; Kempin, S; Spiess, T; Weiss, M | 1 |
| Doorduijn, JK; Michiels, JJ | 1 |
| Binet, JL | 1 |
| Hakimian, D; Tallman, MS | 1 |
| Rai, KR | 1 |
| Brisou, P; de Jaureguiberry, JP; Gisserot, O; Hequet, O; Jaubert, D; Muzellec, Y | 1 |
| Antich Rojas, J; Balaguer, H; Cladera, A | 1 |
| Begleiter, A; Daeninck, P; Israels, LG; Johnston, JB; Lee, K; Mowat, MR; Verburg, L; Williams, G | 1 |
| Losonczy, H | 1 |
| Baudet, S; Binet, JL; Blanc, C; Issaly, F; Mentz, F; Merle-Beral, H | 1 |
| Catovsky, D; Killick, S; Matutes, E; Sternberg, AJ; Wotherspoon, AC | 1 |
| Miller, M | 1 |
| Callea, I; Console, G; Filangeri, M; Messina, G; Morabito, F; Sculli, G | 1 |
| Bentley, P; Davies, S; Hidalgo de Quintana, J; Hoy, T; Pepper, C; Thomas, A | 1 |
| Calvo Villas, J; Ramírez Sánchez, M; Sicilia Guillén, F | 1 |
| Belanger, C; François, S; Hermine, O; Lebas de La Cour, JC; Lefrère, F; Tilly, H; Troussard, X; Valensi, F; Varet, B | 1 |
| Bosanquet, AG; Bosanquet, MI | 1 |
| Cerretti, R; Coluzzi, S; Foa, R; Giannarelli, D; Girelli, G; Mandelli, F; Mauro, FR | 1 |
| Beer, M; Byrd, JC; Grever, MR; Lucas, MA; Waselenko, JK | 1 |
| Koski, T; Vilpo, J; Vilpo, L | 1 |
| Appelbaum, FR; Cheson, BD; Elias, L; Hines, J; Kolitz, J; Larson, RA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L; Threatte, GA | 1 |
| Binet, JL; Dighiero, G | 1 |
| Weiss, MA | 1 |
| Barosi, G; Liberato, LN; Marchetti, M | 1 |
| Copur, MS; Ledakis, P; Muhvic, J | 1 |
| Celik, I; Erman, M; Tekuzman, G | 1 |
| Mounter, P; Proctor, SJ; Summerfield, GP | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Lehman, T; Lucas, D; Sausville, E; Shinn, C; Willis, CR | 1 |
| Emmerich, B; Hallek, M; Schmitt, B; Stein, H | 1 |
| Hallek, M; Schmitt, B | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Martell, RE; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Owen, RG | 1 |
| Battista, C; Broccia, G; Capalbo, S; Castoldi, G; Cuneo, A; Leoni, P; Liso, V; Molica, S; Montillo, M; Pogliani, E; Specchia, G | 1 |
| Champain, K; Csermak, K; Ganeshaguru, K; Gordon, M; Hart, SM; Hoffbrand, AV; Jones, DT; Man, A; Mehta, AB; Prentice, HG; Virchis, AE; Wickremasinghe, RG | 1 |
| Mounter, PJ; Proctor, SJ; Summerfield, GP; Taylor, PR | 1 |
| Dwyer, KM; Firkin, F; Hill, PA; Lee, P; Murphy, BF | 1 |
| Kasznicki, M; Robak, T | 1 |
| Bosanquet, AG; Bosanquet, MI; Daniel, PT; Dörken, B; Essmann, F; Head, DJ; Sturm, I; Wieder, T | 1 |
| Hallek, M | 1 |
| Barlogie, B; Desikan, KR; Dhodapkar, MV | 1 |
| Bergmann, M; Busch, R; Emmerich, B; Franke, A; Hallek, M; Hiddemann, W; Hopfinger, G; Pasold, R; Schlag, R; Schmitt, B; Wendtner, CM | 1 |
| Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Appelbaum, FR; Elias, L; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, KR; Schiffer, CA; Shepherd, L | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Kovacs, MJ; Wells, T | 1 |
| Bosanquet, AG; Daniel, PT; Dörken, B; Güner, D; Hermann, S; Sturm, I | 1 |
| Addison, E; Folarin, NI; Ganeshaguru, K; Hoffbrand, AV; Jones, DT; Lowdell, MW; Mehta, AB; North, JM; Wickremasinghe, RG | 1 |
| Bergmann, M; Emmerich, B; Fingerle-Rowson, G; Goede, V; Hallek, M; Schmitt, B; Schweighofer, C; Wendtner, CM | 1 |
| Begleiter, A; Gibson, SB; Hu, X; Johnston, JB; Kabore, AF; Kropp, DM; Kuschak, B; Paul, JT; Strutinsky, J | 1 |
| Stiefelhagen, P | 1 |
| Ferry-Dumazet, H; Mamani-Matsuda, M; Marit, G; Molimard, M; Mossalayi, MD; Moynet, D; Reiffers, J | 1 |
| Chen, JB; Kaushal, GP; Kurten, RC; Lacy, HM; Schichman, SA; Zent, CS | 1 |
| Nicolle, A; Proctor, SJ; Summerfield, GP | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Cheang, M; Gibson, SB; Haney, N; Hu, X; Johnston, JB; Kropp, DM; Neufeld, NJ; Paul, JT | 1 |
| Ayyildiz, O; Bolaman, Z; Isikdogan, A; Muftuoglu, E | 1 |
| Jaeger, U; Johnson, SA; Leblond, V; Levy, V; Oscier, DG; Owen, RG; Seymour, JF | 1 |
| Arbiser, J; Battle, TE; Frank, DA | 1 |
| Molica, S; Ribatti, D; Tucc, L; Vacca, A | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Boudreaux, CW; Michael, CW; Richardson, PH | 1 |
| Goor, KM; Huijgens, PC; Schaafsma, MR; van Agthoven, M | 1 |
| Cho, HS; Chun, SH; Hyun, MS; Kim, KO; Kim, MK; Lee, KH; Shin, SJ | 1 |
| Barbarotto, E; Corallini, F; di Iasio, MG; Melloni, E; Secchiero, P; Tiribelli, M; Zauli, G | 1 |
| Bernardi, P; Cabrelle, A; Cesura, AM; Colonna, R; Costantini, P; Gambalunga, A; Milanesi, E; Petronilli, V; Pinard, E; Semenzato, G | 1 |
| Bohlius, J; Greil, R; Pall, G; Richards, S; Schwarzer, G; Steurer, M | 1 |
| Kay, NE; O'Brien, S; Rai, KR | 1 |
| Celsing, F; Hansson, L; Karlsson, C; Lundin, J | 1 |
| Arkenau, HT; Chau, I; Cunningham, D; Gordon, C; Norman, A; Wotherspoon, A | 1 |
| Bezares, RF; Bosanquet, AG; Brito-Babapulle, V; Catovsky, D; Child, JA; Davis, Z; Dearden, CE; Dyer, M; Else, M; Hamblin, T; Hamilton, MS; Hillmen, P; Matutes, E; Milligan, DW; Oscier, D; Pettitt, AR; Richards, S; Smith, AG; Wade, R | 1 |
| Austen, B; Baker, C; Dyer, M; Gardiner, A; Majid, A; Moss, PA; Oscier, D; Powell, JE; Siebert, R; Skowronska, A; Stankovic, T; Taylor, AM | 1 |
| Byrd, JC; Flynn, JM | 1 |
| Catovsky, D; Dearden, C; Else, M; Hamblin, T; Milligan, D; Richards, S; Wade, R | 1 |
| Barbarotto, E; Celeghini, C; Corallini, F; Fadda, R; Grill, V; Mischiati, C; Rimondi, E; Vaccarezza, M | 1 |
| Alexandrescu, DT; Wiernik, PH | 1 |
| Cwynarski, K; Duke, VM; Hart, SM; Hoffbrand, AV; Howard-Reeves, JD; Kottaridis, PD; Nacheva, EP; Prentice, AG; Steele, AJ; Vassilev, LT; Wickremasinghe, RG; Yogashangary, BC | 1 |
| Bauduer, F | 1 |
| Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Butters, TD; Ganeshaguru, K; Gerrard, G; Mehta, AB | 1 |
| Boelens, J; Bracke, M; Derycke, L; Janssens, A; Lust, S; Offner, F; Philippé, J; Van Bockstaele, F; Van Gele, M; Vanhoecke, B | 1 |
| Castejón, R; Citores, MJ; García-Marco, JA; Vargas, JA; Villarreal, M; Yebra, M | 1 |
| Elliott, P; Haines, I; Stanley, R | 1 |
| Bergmann, MA; Brittinger, G; Burkhard, O; Busch, R; Döhner, H; Eichhorst, BF; Emmerich, B; Fink, AM; Fischer, K; Goede, V; Hallek, M; Kranzhöfer, N; Ritgen, M; Rohrberg, R; Schweighofer, CD; Söling, U; Stauch, M; Stilgenbauer, S; Wendtner, CM; Westermann, A | 1 |
| Harnalikar, M; Kharkar, V; Khopkar, U; Pande, S | 1 |
| Kosseifi, SG; Krishnaswamy, G; Smith, S; Vyas, B; Vyas, H | 1 |
| Tam, CS | 1 |
| Brychtová, Y; Doubek, M; Mayer, J; Panovská, A | 1 |
| Anderson, KC; Ghobrial, IM; Rourke, M | 1 |
| Gertz, MA | 1 |
| Peinert, S; Seymour, JF | 1 |
| Aloyz, R; Amrein, L; Assouline, S; Caplan, S; Desjardins, P; Egorin, MJ; Hebb, J; Panasci, L; Rousseau, C | 1 |
| Catovsky, D; Dearden, CE; Gonzalez, D; Hockley, S; Martinez, P; Matutes, E; Morgan, GJ; Oscier, D; Richards, SM; Wade, R | 1 |
| Baldini, L; Cortelezzi, A; Gritti, G; Maura, F; Molica, S; Neri, A; Piciocchi, A; Reda, G | 1 |
| Hollweg, A; Rai, KR | 1 |
| Catovsky, D; Cocks, K; Crofts, S; Else, M; Richards, SM; Smith, AG; Wade, R | 1 |
| Bauer, K; Elter, T; Engert, A; Hallek, M; Monsef, I; Roloff, V; Skoetz, N | 1 |
| Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J | 1 |
| Adamson, J; Carter, A; Catovsky, D; Dearden, C; Gonzalez, D; Johnson, GG; Lin, K; Matutes, E; Oates, M; Oscier, DG; Pettitt, AR; Richards, S; Wade, R | 1 |
| Andrieux, J; Baranger, L; Barin, C; Bilhou-Nabera, C; Blons, H; Callet-Bauchu, E; Chapiro, E; Chevret, S; Chiesa, J; Daudignon, A; Eclache, V; Gachard, N; Grelier, A; Henry, C; Lambert, J; Leblondon, V; Lejeune, J; Luquet, I; Merle-Beral, H; Mossafa, H; Mould, S; Mozziconacci, MJ; Mugneret, F; Nguyen-Khac, F; Owen, R; Penther, D; Struski, S; Terre, C; Veronese, L | 1 |
| Catovsky, D; Collins, A; Cross, NC; Else, M; Forster, J; Gardiner, A; Gomez, B; Gonzalez de Castro, D; Oscier, DG; Parker, A; Parker, H; Rose-Zerilli, MJ; Strefford, JC; Winkelmann, N | 1 |
| Ahmed, G; Davis, Z; Dyer, M; Gonzalez, D; Matutes, E; Moss, P; Oldreive, C; Oscier, D; Parker, A; Richards, S; Skowronska, A; Stankovic, T; Taylor, AM; Thomas, P | 1 |
| Appelbaum, FR; Belch, AR; Byrd, JC; Geyer, S; Kolitz, J; Larson, RA; Lin, TS; Morrison, VA; Rai, K; Ruppert, AS; Tallman, MS; Woyach, JA | 1 |
| Chevret, S; Choquet, S; Copplestone, A; Dartigeas, C; Dilhuydy, MS; Ewings, M; Johnson, S; Leblond, V; Lejeune, J; Malphettes, M; Morel, P; Nguyen-Khac, F; Owen, RG; Patmore, RD; Pratt, G; Royer, B; Rule, S; Seymour, JF; Tournilhac, O; Willoughby, S; Wright, D | 1 |
| Bouvet, E; Cazin, B; Coiffier, B; Laurent, G; Michallet, AS; Mosser, L; Oberic, L; Salles, G; Schlaifer, D; Ysebaert, L | 1 |
| Streu, E | 1 |
| Brandberg, Y; Gill, D; Hammerström, J; Hertzberg, M; Johansson, H; Juliusson, G; Jønsson, V; Karlsson, K; Liliemark, J; McLennan, R; Mulligan, SP; Norman, J; Strömberg, M; Sundström, G; Uggla, B; Wallvik, J | 1 |
| Hoang, KQ; Momin, F; Reyes, C; Satram-Hoang, S; Skettino, S | 1 |
| Abenhardt, W; Dörfel, S; Grugel, R; Hartmann, H; Knauf, W; Marschner, N; Meyer, D; Münz, M | 1 |
| Byrd, JC; Flynn, JM; Johnson, AJ; Jones, JJ; Woyach, JA | 1 |
| Foltynski, P; Ladyzynski, P; Molik, M | 1 |
| Assaily, W; Bence-Bruckler, I; Chamakhi, I; Christofides, A; Owen, C; Robinson, S; Toze, C | 1 |
| Brown, JR | 1 |
| Mamorska-Dyga, A; Seiter, K | 1 |
| Catovsky, D; Else, M; Oscier, D; Wade, R | 1 |
| Amadori, S; Bittolo, T; Bomben, R; Buccisano, F; Cefalo, M; Dal Bo, M; de Fabritiis, P; De Santis, G; Del Poeta, G; Del Principe, MI; Gaidano, G; Gattei, V; Maurillo, L; Rossi, D; Rossi, FM; Venditti, A; Zucchetto, A | 1 |
| Becker, U; Hautala, A; Kyttälä, M; Martikainen, J; Poikonen, E; Soini, E | 1 |
| Böhme, A; Dreyling, M; Fries, S; Höhler, T; Kellermann, L; Kiewe, P; Zoellner, AK | 1 |
| Bahlo, J; Cramer, P; Eichhorst, B; Engelke, A; Fink, AM; Fischer, K; Hallek, M; Kovacs, G; Langerbeins, P; Maurer, C; Müller, L; Pflug, N; Ritgen, M; Seiler, T; Stilgenbauer, S; von Tresckow, J; Wendtner, CM | 1 |
| Becker, U; Briggs, AH; Moreno, SG; Ngo, P; Ray, JA; Samanta, K | 1 |
| Cao, H; Chen, G; Ding, J; Li, J; Pang, N; Qu, J; Wang, L; Yuan, H; Zhang, R; Zhang, Z; Zhao, F | 1 |
| Becker, U; Miguel, LS; Paquete, AT; Pereira, C; Pinto, CG | 1 |
| Baculea, S; Cote, S; Diels, J; Van Sanden, S | 1 |
| Aktan, M; Bosch, F; Dartigeas, C; Ferra Coll, CM; Foà, R; Gresko, E; Kisro, J; Leblond, V; Merot, JL; Montillo, M; Raposo, J; Robson, S; Stilgenbauer, S | 1 |
| Andersson, PO; Asklid, A; Bjellvi, J; Hansson, L; Johansson, H; Karlsson, C; Karlsson, K; Kimby, E; Klintman, J; Lauri, B; Mattsson, M; Norin, S; Österborg, A; Sandstedt, AB; Strandberg, M; Sylvan, SE; Tolvgård, S | 1 |
| Jain, N | 1 |
| Bishton, MJ; Clifton-Hadley, L; Haynes, A; Lush, R; McMillan, A; Patmore, R; Rule, S; Turner, D; Wilson, W | 1 |
| An, Y; Gao, X; Jingquan, G; Xiao, K; Xie, W; Yang, L | 1 |
| Andersen, MA; da Cunha-Bang, C; Frederiksen, H; Grønbaek, K; Hjalgrim, H; Niemann, CU; Rostgaard, K; Rotbain, EC | 1 |
| Bosch, F; Böttcher, S; Foà, R; Ilhan, O; Kisro, J; Leblond, V; Mahé, B; Mikuskova, E; Osmanov, D; Perretti, T; Reda, G; Robinson, S; Stilgenbauer, S; Tausch, E; Trask, P; Turgut, M; Van Hoef, M; Wójtowicz, M | 1 |
| Burningham, Z; Chien, HC; Halwani, AS; Li, CY; Morreall, D; Passey, DG; Patil, V; Rasmussen, KM; Sauer, BC; Yong, CM | 1 |
26 review(s) available for chlorambucil and vidarabine
| Article | Year |
|---|---|
A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemotherapeutic modalities.
Topics: 2-Chloroadenosine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Chlorambucil; Deoxyadenosines; Dose-Response Relationship, Drug; Histocompatibility Testing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Prednisone; Prognosis; Survival Rate; Vidarabine | 1992 |
[Treatment with cyclosporin A of the anemia associated with chronic lymphatic leukemia].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclosporins; Erythropoiesis; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Red-Cell Aplasia, Pure; T-Lymphocytes, Regulatory; Thrombocytopenia; Vidarabine | 1990 |
Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bone Marrow Transplantation; Chlorambucil; Chromosome Aberrations; Cladribine; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Activation; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Vidarabine | 1995 |
Current results and prospective trials of cladribine in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prospective Studies; Vidarabine | 1996 |
[Current principles of diagnosis and treatment of chronic lymphocytic B-cell leukemia].
Topics: Alkylating Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Vidarabine | 1998 |
Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Synergism; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Remission Induction; Vidarabine | 2000 |
Novel treatment strategies in chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cladribine; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Pentostatin; Randomized Controlled Trials as Topic; Sex Factors; Vidarabine | 2001 |
[Chronic lymphocytic leukemia. 2. Therapy].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bone Marrow Transplantation; Chlorambucil; Dose-Response Relationship, Radiation; Drug Therapy, Combination; Hematopoietic Stem Cell Transplantation; Humans; Immunization, Passive; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Risk Factors; Splenectomy; Steroids; Transplantation, Autologous; Vidarabine | 2001 |
Treatment options in Waldenström's macroglobulinaemia: the role of the purine analogues.
Topics: Alkylating Agents; Antimetabolites; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Resistance; Drug Therapy, Combination; Guidelines as Topic; Humans; Middle Aged; Pentostatin; Plasmapheresis; Purine Nucleosides; Quality of Life; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Therapy, Combination; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Recurrence, Local; Nucleosides; Survival Rate; Treatment Failure; Vidarabine | 2002 |
Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; beta 2-Microglobulin; Chlorambucil; Cladribine; Clinical Trials as Topic; Combined Modality Therapy; Humans; Interferon-alpha; Neoplasm Recurrence, Local; Plasmapheresis; Rituximab; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Chlorambucil; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Forecasting; Granulocyte Colony-Stimulating Factor; Humans; Immunotherapy; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Treatment Outcome; Vidarabine; Vincristine | 2002 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; Bone Marrow Diseases; Chemotherapy, Adjuvant; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Paraproteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2002 |
[Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Combined Modality Therapy; Enzyme Inhibitors; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitrogen Mustard Compounds; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Time Factors; Vidarabine | 2003 |
[Waldenstrom macroglobulinemia].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Blood Transfusion; Chlorambucil; Diagnosis, Differential; Drug Therapy, Combination; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Plasmapheresis; Prednisone; Prognosis; Recurrence; Rituximab; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2004 |
Economic assessment on the management of chronic lymphocytic leukaemia.
Topics: Algorithms; Antibodies, Monoclonal; Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Health Care Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Stem Cell Transplantation; Vidarabine | 2005 |
Purine antagonists for chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Chlorambucil; Cladribine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Pentostatin; Randomized Controlled Trials as Topic; Vidarabine | 2006 |
Chronic lymphocytic leukemia: current and emerging treatment approaches.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Disease-Free Survival; Drug Screening Assays, Antitumor; Flow Cytometry; Gene Expression Regulation, Leukemic; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Polymerase Chain Reaction; Risk Factors; Survival Rate; Trisomy; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2006 |
Tumor lysis syndrome following chlorambucil therapy for chronic lymphocytic leukemia: case report and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Risk Factors; Tumor Lysis Syndrome; Vidarabine | 2009 |
Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Alemtuzumab for patients with chronic lymphocytic leukaemia.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2012 |
Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Topics: Adenine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Gene Deletion; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Nitrogen Mustard Compounds; Piperidines; Practice Patterns, Physicians'; Purines; Pyrazoles; Pyrimidines; Quinazolinones; Vidarabine | 2014 |
A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Nitrogen Mustard Compounds; Pentostatin; Physical Fitness; Proportional Hazards Models; Randomized Controlled Trials as Topic; Rituximab; Vidarabine | 2015 |
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.
Topics: Adenine; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Canada; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Vidarabine | 2015 |
Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia.
Topics: Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD20; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Chlorambucil; Clinical Trials as Topic; Comorbidity; Disease-Free Survival; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Vidarabine | 2015 |
Selecting Frontline Therapy for CLL in 2018.
Topics: Adenine; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Smith-Magenis Syndrome; Vidarabine | 2018 |
27 trial(s) available for chlorambucil and vidarabine
| Article | Year |
|---|---|
Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Humans; Ifosfamide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Melphalan; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pilot Projects; Prednisolone; Prednisone; Remission Induction; Staining and Labeling; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Vidarabine; Vinca Alkaloids; Vincristine | 1995 |
Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs.
Topics: Antineoplastic Agents; B-Lymphocytes; Camptothecin; Cell Survival; Cells, Cultured; Chlorambucil; Genes, p53; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Neoplasm Staging; Sensitivity and Specificity; Tumor Cells, Cultured; Vidarabine | 1994 |
When and how to treat elderly patients with chronic lymphocytic leukemia (C.L.L.)? The French Cooperative Group on C.L.L.
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Multivariate Analysis; Neoplasm Staging; Peptichemio; Prednisone; Sex Factors; Vidarabine; Vincristine | 1993 |
A randomized phase II trial of high-dose chlorambucil vs. fludarabine in patients with advanced B-chronic lymphocytic leukemia. EORTC Leukemia Cooperative Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Chlorambucil; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasm Staging; Pilot Projects; Vidarabine | 1999 |
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cross-Over Studies; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Analysis; Vidarabine | 2000 |
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Ontario; Respiratory Tract Infections; Skin Diseases, Infectious; Treatment Outcome; United States; Vidarabine | 2001 |
[Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Rate; Treatment Outcome; Vidarabine | 2002 |
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Clinical Trials, Phase III as Topic; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Vidarabine | 2002 |
Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Female; Humans; Lymphoma; Male; Middle Aged; Prospective Studies; Splenic Neoplasms; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Survival Analysis; Vidarabine | 2007 |
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Coombs Test; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine | 2008 |
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Chlorambucil; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Remission Induction; Survival Rate; Vidarabine | 2009 |
A phase I study of imatinib mesylate in combination with chlorambucil in previously treated chronic lymphocytic leukemia patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chlorambucil; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrimidines; Rad51 Recombinase; Recombination, Genetic; Treatment Outcome; Vidarabine | 2011 |
Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; DNA Mutational Analysis; Genes, p53; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Proportional Hazards Models; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Cytomegalovirus; Cytomegalovirus Infections; Dose-Response Relationship, Immunologic; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Subcutaneous; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Salvage Therapy; Vidarabine; Virus Activation | 2012 |
Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Fatigue; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; Vidarabine; Vomiting | 2012 |
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Female; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotype; Male; Middle Aged; Prognosis; Prospective Studies; Trisomy; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Chromosomes, Human, Pair 12; Cyclophosphamide; Education, Medical, Continuing; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Membrane Glycoproteins; Middle Aged; Phosphoproteins; Prognosis; Receptor, Notch1; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Trisomy; Tumor Suppressor Protein p53; Vidarabine | 2013 |
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclophosphamide; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Serine-Threonine Kinases; Survival Analysis; Tumor Suppressor Proteins; United Kingdom; Vidarabine | 2012 |
Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Proportional Hazards Models; Vidarabine; Waldenstrom Macroglobulinemia | 2013 |
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cladribine; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Quality of Life; Retreatment; Treatment Outcome; Vidarabine | 2014 |
The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL.
Topics: Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Case-Control Studies; Cell Transformation, Neoplastic; Chlorambucil; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasms, Second Primary; Registries; Risk Assessment; Risk Factors; Vidarabine | 2016 |
Safety of obinutuzumab alone or combined with chemotherapy for previously untreated or relapsed/refractory chronic lymphocytic leukemia in the phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2018 |
First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 17; Cyclophosphamide; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisolone; Registries; Retrospective Studies; Rituximab; Survival Rate; Sweden; Vidarabine | 2019 |
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Progression-Free Survival; Prospective Studies; Survival Rate; United Kingdom; Vidarabine; Young Adult | 2020 |
Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Biomarkers, Pharmacological; Chlorambucil; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Neutropenia; Non-Randomized Controlled Trials as Topic; Progression-Free Survival; Recurrence; Safety; Thrombocytopenia; Treatment Outcome; Vidarabine | 2021 |
91 other study(ies) available for chlorambucil and vidarabine
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-beta-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro.
Topics: Antineoplastic Agents; Biological Transport; Bone Marrow; Cell Survival; Cells, Cultured; Chlorambucil; Cladribine; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 1995 |
CD23 antigen density is related to serum gamma globulin level, bone marrow reticulin pattern, and treatment in B chronic lymphocytic leukemia.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Flow Cytometry; Fluorescent Antibody Technique; gamma-Globulins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm Staging; Prednisolone; Receptors, IgE; Reticulin; Vidarabine; Vincristine | 1994 |
Modulation of purine analogs- and chlorambucil-induced cytotoxicity by alpha-interferon and interleukin-2 in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Humans; Interferon-alpha; Interleukin-1; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Tumor Necrosis Factor-alpha; Vidarabine | 1995 |
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance.
Topics: 2-Chloroadenosine; Aged; Chlorambucil; Drug Resistance; Erythrocyte Transfusion; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Time Factors; Vidarabine | 1994 |
Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recurrence; Vidarabine | 1994 |
Effectiveness of fludarabine in end-stage prolymphocytic leukemia.
Topics: Aged; Anemia; Antigens, CD; Antineoplastic Agents; Blood Transfusion; Chlorambucil; Female; Humans; Immunophenotyping; Leukemia, Prolymphocytic; Neoplasm Staging; Splenectomy; Thrombocytopenia; Vidarabine | 1994 |
Chronic lymphocytic leukemia in the elderly population.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Female; Humans; Incidence; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisone; United States; Vidarabine | 1997 |
Listeriosis after fludarabine treatment for chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Listeriosis; Prednisone; Sulfamethoxazole; Trimethoprim; Vidarabine; Vincristine | 1997 |
[Selective aplasia of the red-cell series after fludarabine administration in a patient with chronic B-cell lymphatic leukemia].
Topics: Anemia, Hemolytic, Autoimmune; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Chlorambucil; Cyclophosphamide; Cyclosporine; Doxorubicin; Humans; Hydrocortisone; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Red-Cell Aplasia, Pure; Vidarabine; Vincristine | 1997 |
P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; bcl-2-Associated X Protein; Chlorambucil; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single-Stranded Conformational; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 1997 |
Simple, fast method of detection apoptosis in lymphoid cells.
Topics: Apoptosis; Blood Cell Count; Cells, Cultured; Chlorambucil; Flow Cytometry; Humans; Immunohistochemistry; Interleukin-4; Jurkat Cells; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Reference Values; Scattering, Radiation; Theophylline; Vidarabine | 1998 |
Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vidarabine; Vincristine | 1998 |
When prognosis is poor, does false hope add to leukemia patients' pain?
Topics: Adaptation, Psychological; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 1998 |
Chlorambucil synergizes with purine analogs in inducing in vitro cytotoxicity in B-cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplastic Stem Cells; Tumor Cells, Cultured; Vidarabine | 1998 |
Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chlorambucil; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
[Chronic lymphatic leukemia and Hodgkin's disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlorambucil; Dacarbazine; Doxorubicin; Female; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Neoplasms, Second Primary; Prednisone; Remission Induction; Vidarabine; Vinblastine | 1999 |
Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunologic Factors; Interferon-alpha; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Vidarabine | 2000 |
Ex vivo assessment of drug response by differential staining cytotoxicity (DiSC) assay suggests a biological basis for equality of chemotherapy irrespective of age for patients with chronic lymphocytic leukaemia.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Chlorambucil; Cladribine; Comorbidity; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Middle Aged; Neoplastic Stem Cells; Palliative Care; Pentostatin; Prednisolone; Prognosis; Staining and Labeling; Tumor Cells, Cultured; Vidarabine; Vincristine | 2000 |
Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multivariate Analysis; Prednisolone; Probability; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Survival Analysis; Time Factors; Vidarabine | 2000 |
Calcium antagonists potentiate P-glycoprotein-independent anticancer drugs in chronic lymphocytic leukemia cells in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium; Calcium Channel Blockers; Calcium Signaling; Chlorambucil; Cisplatin; Cladribine; Cyclosporine; DNA Fragmentation; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nifedipine; Prednisolone; Tumor Cells, Cultured; Verapamil; Vidarabine; Vincristine | 2000 |
When and how to treat chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Vidarabine | 2000 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; Humans; Italy; Leukemia, Lymphocytic, Chronic, B-Cell; Value of Life; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Remission Induction; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Age Factors; Antineoplastic Agents; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Palliative Care; Remission Induction; Vidarabine | 2001 |
Fludarabine for chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Chlorambucil; Drug Administration Schedule; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2001 |
UCN-01 induces cytotoxicity toward human CLL cells through a p53-independent mechanism.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Multiple; Genes, bcl-2; Humans; Interleukin-4; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Inbred C57BL; Mice, Knockout; Prednisone; Proto-Oncogene Proteins c-bcl-2; Spleen; Staurosporine; Thymus Gland; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vidarabine | 2001 |
[Chronic lymphatic leukemia. 3. The concrete case].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Prognosis; Vidarabine | 2001 |
Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Retrospective Studies; Treatment Outcome; Vidarabine; Vincristine | 2001 |
Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro.
Topics: 2-Chloroadenosine; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Calcium Channel Blockers; Chlorambucil; Deoxyadenosines; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Female; Humans; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Proteins; Palatine Tonsil; Protein Kinase C; Staurosporine; Tumor Cells, Cultured; Verapamil; Vidarabine | 2002 |
High-dose chlorambucil for the treatment of chronic lymphocytic leukaemia and low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antineoplastic Agents, Alkylating; Chlorambucil; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Vidarabine | 2002 |
Membranoproliferative glomerulonephritis in association with chronic lymphocytic leukaemia: a report of three cases.
Topics: Adult; Aged; Antineoplastic Agents; Chlorambucil; Drug Therapy, Combination; Female; Glomerular Mesangium; Glomerulonephritis, Membranoproliferative; Humans; Kidney Glomerulus; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microscopy, Fluorescence; Middle Aged; Paraproteinemias; Prednisolone; Treatment Outcome; Vidarabine | 2002 |
Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Chlorambucil; Cladribine; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Glucocorticoids; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2002 |
Chronic lymphocytic leukaemia: only treat when symptomatic.
Topics: Adult; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Life Expectancy; Male; Meta-Analysis as Topic; Middle Aged; Treatment Outcome; Vidarabine | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Autoimmune thrombocytopenia due to chronic lymphocytic leukemia treated with fludarabine.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Purpura, Thrombocytopenic, Idiopathic; Time Factors; Vidarabine | 2003 |
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Chlorambucil; Cyclophosphamide; DNA Damage; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gamma Rays; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Risk Factors; Survival Rate; Tumor Suppressor Protein p53; Vidarabine | 2003 |
Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs.
Topics: Antibiotics, Antineoplastic; Antigens, CD34; Apoptosis; Benzoquinones; Blotting, Western; Bone Marrow Cells; Cell Separation; Chlorambucil; Down-Regulation; Enzyme Inhibitors; Flow Cytometry; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinones; Rifabutin; RNA, Messenger; T-Lymphocytes; Time Factors; Tumor Suppressor Protein p53; Up-Regulation; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Chlorambucil; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Protein Binding; RNA, Messenger; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vidarabine | 2003 |
[Pressure pain in the left epigastrium: blood picture provides diagnosis. Chronic lymphatic leukemia].
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytosis; Lymphocyte Count; Male; Middle Aged; Prednisone; Splenomegaly; Time Factors; Ultrasonography; Vidarabine | 2003 |
Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells.
Topics: Adrenergic beta-Agonists; Aged; Aged, 80 and over; Albuterol; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Calcium; Cell Line, Tumor; Chlorambucil; Cyclic AMP; Ethanolamines; Female; Formoterol Fumarate; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Vidarabine | 2004 |
Alemtuzumab (CAMPATH 1H) does not kill chronic lymphocytic leukemia cells in serum free medium.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chlorambucil; Complement System Proteins; Culture Media, Serum-Free; Humans; Immunoglobulin Fab Fragments; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2004 |
High dose chlorambucil in the treatment of lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Lymphoid; Lymphoma; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Vidarabine | 2004 |
Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cell Survival; Cells, Cultured; Chlorambucil; Drug Resistance, Neoplasm; Female; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasm Staging; Predictive Value of Tests; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2004 |
Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Chlorambucil; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Prednisolone; Retreatment; Survival Analysis; Turkey; Vidarabine | 2004 |
Fludarabine: new indication. First-line treatment of CLL: unconvincing evidence.
Topics: Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; France; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Pentostatin; Randomized Controlled Trials as Topic; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2005 |
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Caspases; Chlorambucil; Cladribine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Humans; In Vitro Techniques; Interleukin-4; Leukemia, Lymphocytic, Chronic, B-Cell; Lignans; Magnolia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Phytotherapy; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 2005 |
Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow; Chlorambucil; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Microcirculation; Middle Aged; Neoplasm, Residual; Neovascularization, Pathologic; Vidarabine | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
Pulmonary lymphoma of the mucosa-associated lymphoid tissue type: Report of a case with cytological, histological, immunophenotypical correlation, and review of the literature.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Treatment Outcome; Vidarabine; Vincristine | 2005 |
Myelodysplastic syndrome with complex karyotypic abnormality in a patient with Waldenström's macroglobulinemia after sequential treatment with chlorambucil and fludarabine.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chlorambucil; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Drug Administration Schedule; Humans; Male; Monosomy; Myelodysplastic Syndromes; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carrier Proteins; Cell Survival; Chlorambucil; Flow Cytometry; Gene Expression; Glycoproteins; Humans; Immunoglobulin G; Interleukin-1; Interleukin-8; Leukemia, Lymphocytic, Chronic, B-Cell; Membrane Glycoproteins; Oligonucleotide Array Sequence Analysis; Osteoprotegerin; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2006 |
The mitochondrial effects of small organic ligands of BCL-2: sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative.
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Barbiturates; bcl-2-Associated X Protein; Benzophenanthridines; Benzopyrans; Caspase 9; Caspases; Cell Line; Cell Line, Tumor; Cell Survival; Chlorambucil; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; HeLa Cells; Humans; Ligands; Membrane Potentials; Microscopy, Fluorescence; Mitochondria; Phenanthridines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rats; Rats, Wistar; RNA, Small Interfering; Staurosporine; Time Factors; Vidarabine | 2006 |
Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Topics: Aged; Alemtuzumab; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; CD52 Antigen; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Drug Resistance; Glycoproteins; Hemoglobins; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prednisone; Splenectomy; Treatment Outcome; Vidarabine; Vincristine | 2007 |
Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2007 |
Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion.
Topics: Aged; Alleles; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Cyclophosphamide; DNA Breaks, Double-Stranded; DNA-Binding Proteins; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins; Vidarabine | 2007 |
Have we forgotten the purpose of phase III studies?
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; CD52 Antigen; Chlorambucil; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Research Design; Vidarabine | 2007 |
Differential effects of chemotherapeutic drugs versus the MDM-2 antagonist nutlin-3 on cell cycle progression and induction of apoptosis in SKW6.4 lymphoblastoid B-cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B-Lymphocytes; Blast Crisis; Cell Cycle; Cell Line, Tumor; Chlorambucil; Humans; Imidazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Piperazines; Proto-Oncogene Proteins c-mdm2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; Vidarabine | 2008 |
Serum globulins as marker of immune restoration after treatment with high-dose rituximab for chronic lymphocytic leukemia.
Topics: Agammaglobulinemia; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Biomarkers; Chlorambucil; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Serum Globulins; Vidarabine | 2008 |
p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Apoptosis Regulatory Proteins; Benzothiazoles; Chlorambucil; Female; Humans; In Vitro Techniques; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Toluene; Transcription, Genetic; Tumor Suppressor Protein p53; Vidarabine | 2008 |
[First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
Topics: Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cyclophosphamide; Drug Costs; Frail Elderly; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloablative Agonists; Opportunistic Infections; Risk Factors; Rituximab; Vidarabine | 2009 |
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine | 2008 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Glucosylceramide synthase inhibitors sensitise CLL cells to cytotoxic agents without reversing P-gp functional activity.
Topics: 1-Deoxynojirimycin; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; B-Lymphocytes; Cell Line, Tumor; Chlorambucil; Cytotoxins; Enzyme Inhibitors; Female; Fluoresceins; Fluorescent Dyes; Formazans; Glucosyltransferases; Humans; Inhibitory Concentration 50; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Models, Chemical; Molecular Structure; Tetrazolium Salts; Vidarabine | 2009 |
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Topics: Adrenal Cortex Hormones; Annexin A5; Apoptosis; Chlorambucil; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Enzymologic; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Methylprednisolone; Plasmids; Prognosis; Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Syk Kinase; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2009 |
Drug induction apoptosis assay as predictive value of chemotherapy response in patients with B-cell chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Chlorambucil; Cladribine; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prognosis; Time Factors; Tumor Cells, Cultured; Vidarabine | 2009 |
A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Conflict of Interest; Cost-Benefit Analysis; Cross-Over Studies; Cyclophosphamide; Disease-Free Survival; Drug Costs; Hospital Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Practice Guidelines as Topic; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Vidarabine | 2009 |
Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis.
Topics: Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Diagnosis, Differential; Fluorescent Antibody Technique, Direct; Foot Diseases; Humans; Immunoglobulin M; Keratosis; Male; Middle Aged; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
In defence of the use of modern chemotherapy regimens for the treatment of patients with chronic lymphocytic leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Treatment Outcome; Vidarabine | 2009 |
Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL).
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Czech Republic; Disease Management; Female; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine | 2010 |
What's new in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Unresolved issues in the comparison of therapies and determination of responses in Waldenström macroglobulinemia.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Chlorambucil; Cladribine; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Rituximab; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2010 |
Fludarabine versus chlorambucil: is the debate over?
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Remission Induction; Vidarabine | 2011 |
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Radiotherapy, Conformal; Spleen; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclin-Dependent Kinase Inhibitor p21; Cyclophosphamide; DNA-Binding Proteins; Female; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocytes, Mononuclear; Male; Middle Aged; Mutation; Prognosis; Protein Serine-Threonine Kinases; Randomized Controlled Trials as Topic; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vidarabine | 2012 |
Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Aging; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Randomized Controlled Trials as Topic; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2013 |
First immunochemotherapy outcomes in elderly patients with CLL: a retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Chromosome Deletion; Chromosomes, Human, Pair 11; Comorbidity; Creatinine; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Multivariate Analysis; Myelodysplastic Syndromes; Neutropenia; Retrospective Studies; Rituximab; Vidarabine | 2013 |
Second malignancies in chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chlorambucil; Combined Modality Therapy; Ear Neoplasms; Early Diagnosis; Humans; Immunocompromised Host; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemic Infiltration; Male; Neoplasms, Second Primary; Risk; Rituximab; Skin; Skin Neoplasms; Vidarabine | 2014 |
Treatment practice in the elderly patient with chronic lymphocytic leukemia-analysis of the combined SEER and Medicare database.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Comorbidity; Cyclophosphamide; Databases, Factual; Disease Management; Doxorubicin; Ethnicity; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Medicare; Practice Patterns, Physicians'; Prednisone; Rituximab; SEER Program; Socioeconomic Factors; Treatment Outcome; United States; Vidarabine; Vincristine | 2014 |
Routine treatment of patients with chronic lymphocytic leukaemia by office-based haematologists in Germany-data from the Prospective Tumour Registry Lymphatic Neoplasms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Cyclophosphamide; Female; Germany; Hematology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Nitrogen Mustard Compounds; Office Visits; Prednisone; Prospective Studies; Registries; Rituximab; Vidarabine | 2015 |
Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Remission Induction; Rituximab; Vidarabine | 2015 |
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Rituximab; Survival Rate; Vidarabine | 2016 |
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bayes Theorem; Chlorambucil; Contraindications; Cost-Benefit Analysis; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine | 2016 |
Altered treatment of chronic lymphocytic leukemia in Germany during the last decade.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Chlorambucil; Female; Germany; Health Care Surveys; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine | 2016 |
Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cost-Benefit Analysis; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Markov Chains; Meta-Analysis as Topic; Middle Aged; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; Treatment Outcome; United Kingdom; Vidarabine | 2016 |
Increased IL-10/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Female; Forkhead Transcription Factors; Humans; Immunosuppressive Agents; Interleukin-10; Interleukin-17; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Nuclear Receptor Subfamily 1, Group F, Member 3; Prognosis; Rituximab; T-Lymphocytes, Regulatory; Th17 Cells; Vidarabine | 2016 |
Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients who are Unsuitable for Full-Dose Fludarabine-Based Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Health Care Costs; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Markov Chains; Quality-Adjusted Life Years; Rituximab; Vidarabine | 2017 |
Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Bayes Theorem; Chlorambucil; Disease-Free Survival; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrazoles; Pyrimidines; Vidarabine | 2017 |
HuR Affects Proliferation and Apoptosis of Chronic Lymphocytic Leukemia Cells via NF-
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Chlorambucil; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Humans; I-kappa B Kinase; Leukemia, Lymphocytic, Chronic, B-Cell; NF-kappa B; NF-kappaB-Inducing Kinase; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; TNF Receptor-Associated Factor 1; Tumor Necrosis Factor-alpha; Up-Regulation; Vidarabine | 2020 |
Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bendamustine Hydrochloride; Chlorambucil; Cohort Studies; Denmark; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Registries; Risk Assessment; Survival Analysis; Vidarabine | 2021 |
Real-world treatment patterns and outcomes in a national study of veterans with Waldenström macroglobulinemia, 2006-2019.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bortezomib; Chlorambucil; Cyclophosphamide; Dexamethasone; Doxorubicin; Humans; Kaplan-Meier Estimate; Piperidines; Prednisone; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Rituximab; Treatment Outcome; Veterans; Vidarabine; Vincristine; Waldenstrom Macroglobulinemia | 2021 |